Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 83
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Br J Dermatol ; 178(1): 238-244, 2018 01.
Artículo en Inglés | MEDLINE | ID: mdl-28391642

RESUMEN

BACKGROUND: Little is known about factors affecting the quality of life (QoL) of patients with vitiligo, and previous studies have shown conflicting results. OBJECTIVES: To explore the QoL of patients with vitiligo and to identify factors affecting QoL. METHODS: A nationwide questionnaire-based study was conducted with 1123 patients with vitiligo recruited from 21 hospitals in Korea from July 2015 to June 2016. Data were collected using a structured questionnaire for demographic information and the Skindex-29 instrument. Mild or severely impaired QoL in patients with vitiligo was assessed according to each domain (symptoms, functioning and emotions) of Skindex-29. Multivariate logistic regression analyses were performed to determine the factors associated with QoL. RESULTS: Of the enrolled participants, 609 were male and 514 female, with a mean age of 49·8 years (range 20-84). The median duration of disease was 3·0 years (range 0-60). Using multivariate logistic regression modelling, the involvement of visible body parts and a larger affected body surface area were consistently associated with QoL impairment in all three domains of Skindex-29. Additionally, the QoL of patients aged 20-59 years, who potentially had a more active social life than older patients, was associated with functional impairment. Furthermore, a higher educational background was associated with emotional impairment. CONCLUSIONS: A multitude of factors significantly influence the QoL of patients with vitiligo. A better appreciation of these factors would help the management of these patients.


Asunto(s)
Calidad de Vida/psicología , Vitíligo/psicología , Adulto , Distribución por Edad , Anciano , Anciano de 80 o más Años , Ansiedad/etiología , Actitud Frente a la Salud , Imagen Corporal/psicología , Emociones , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fenotipo , República de Corea/epidemiología , Distribución por Sexo , Factores Socioeconómicos , Encuestas y Cuestionarios , Vitíligo/epidemiología , Adulto Joven
3.
Clin Exp Dermatol ; 40(3): 279-85, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25532463

RESUMEN

BACKGROUND: Hair is known to persist on the occipital and part of the temporal scalp in patients with androgenetic alopecia (AGA), but no quantified data about the follicular changes in such areas exist. AIM: To evaluate the hair characteristics in nonbalding scalp areas in East Asian patients with AGA. METHODS: In total, 265 participants [211 patients with AGA and 50 healthy controls (HCs)] were enrolled. The patients were divided by the Basic and Specific (BASP) classification [four basic types (L, M, C, and U) and two special types (V and F)], and the hair in the occipital region and two sites of the temporal region were analysed by computer-assisted phototrichography. Hair density, hair width, number of each follicular unit, ratio of single to compound hairs and ratio of terminal to vellus hairs were examined. RESULTS: In the temporal region, a statistically significant (P < 0.05) decrease in hair density was observed in patients with C, U or F subtypes, and a significant (P < 0.05) decrease in hair thickness was observed in patients with the U subtype compared with HCs. In the mastoid and occipital areas, both hair density and hair thickness was significantly (P < 0.05) decreased in patients with the U subtype compared with HCs. Within each classification, hairs became generally thinner as the hair loss progressed. CONCLUSIONS: Hair density and hair thickness of known nonbalding scalp regions showed some differences depending on the severity and the BASP subtypes in East Asian people with male pattern baldness.


Asunto(s)
Alopecia/patología , Cabello/patología , Adulto , Distribución por Edad , Anciano , Estudios de Casos y Controles , Humanos , Masculino , Persona de Mediana Edad , Cuero Cabelludo , Adulto Joven
4.
J Viral Hepat ; 21(11): 809-17, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-24329944

RESUMEN

This study sought to assess the antiviral efficacy of lamivudine (LMV) administered during third trimester to reduce maternal viraemia and to identify the emergence of LMV resistance. A prospective observational analysis was performed on 26 mothers with high viral load (>107 IU/mL). Twenty-one women received LMV (treated group) for an average of 53 days (range 22-88 days), and the remaining five formed the untreated control group. Serum samples from two time points were used to measure HBV DNA levels and antiviral drug resistance. The LMV-treated women achieved a median HBV DNA reduction of 2.6-log10 IU/mL. Although end-of-treatment (EOT) HBV DNA in four (18%) LMV-treated women remained at >10(7) IU/mL (± 0.5 log IU/mL), no mother-to-baby transmission was observed. In contrast, a baby from the untreated mother was HBsAg positive at 9 months postpartum. Four technologies were used for drug resistance testing. Only ultra-deep pyrosequencing (UDPS) was sufficiently sensitive to detect minor viral variants down to <1%. UDPS showed that LMV therapy resulted in increased viral quasispecies diversity and positive selection of HBV variants with reverse transcriptase amino acid substitutions at sites associated with primary LMV resistance (rtM204I/V and rtA181T) in four (19%) women. These viral variants were detected mostly at low frequencies (0.63-5.92%) at EOT, but one LMV-treated mother had an rtA181T variant that increased from 2.2% pretherapy to 25.59% at EOT. This mother was also infected with the vaccine escape variant (sG145R), which was inhibited by LMV treatment. LMV therapy during late pregnancy only reduced maternal viraemia moderately, and drug-resistant viral variants emerged.


Asunto(s)
Antivirales/uso terapéutico , Farmacorresistencia Viral , Virus de la Hepatitis B/efectos de los fármacos , Hepatitis B/tratamiento farmacológico , Transmisión Vertical de Enfermedad Infecciosa/prevención & control , Lamivudine/uso terapéutico , Complicaciones Infecciosas del Embarazo/tratamiento farmacológico , Sangre/virología , ADN Viral/genética , ADN Viral/aislamiento & purificación , Femenino , Variación Genética , Hepatitis B/prevención & control , Hepatitis B/virología , Virus de la Hepatitis B/aislamiento & purificación , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Recién Nacido , Mutación , Embarazo , Complicaciones Infecciosas del Embarazo/virología , Estudios Prospectivos , Selección Genética , Resultado del Tratamiento , Carga Viral
5.
Herz ; 39(5): 593-7, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-23732400

RESUMEN

Primary tumors of the great vessels are very rare. Primary leiomyosarcomas of the pulmonary vein are extremely rare and little is known about their clinical manifestation and treatment. We report the case of a 34-year-old patient with primary leiomyosarcoma of the pulmonary vein extending into the left atrium. A review of the clinical manifestation and treatment of 24 cases including our own is provided.


Asunto(s)
Atrios Cardíacos/patología , Leiomiosarcoma/diagnóstico , Leiomiosarcoma/patología , Venas Pulmonares/patología , Neoplasias Vasculares/diagnóstico , Neoplasias Vasculares/patología , Adulto , Ecocardiografía Transesofágica , Femenino , Atrios Cardíacos/cirugía , Humanos , Interpretación de Imagen Asistida por Computador , Leiomiosarcoma/cirugía , Imagen por Resonancia Magnética , Imagen Multimodal , Invasividad Neoplásica , Tomografía de Emisión de Positrones , Venas Pulmonares/diagnóstico por imagen , Tomografía Computarizada por Rayos X , Neoplasias Vasculares/cirugía
6.
Skin Pharmacol Physiol ; 27(3): 132-40, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24434642

RESUMEN

PURPOSE: Ultraviolet (UV) light from sunlight is an important environmental factor causing hazardous health effects, including various skin disorders. UV irradiation downregulates reactive oxygen species (ROS) elimination pathways, thereby promoting the production of ROS, which are implicated in mitochondria-mediated apoptosis. Walnuts, the seeds of Juglandis sinensis L., are a highly nutritious food and have been shown to have a number of pharmacological activities. To our knowledge, no study on the protective effects of walnuts on human epidermal keratinocytes has been reported previously. Here, we investigated the protective effects of walnuts against UVB (50 mJ/cm(2)) -induced mitochondria-mediated apoptosis. PROCEDURES AND RESULTS: Walnuts significantly and dose-dependently reduced UVB-induced apoptotic toxicity by lactate dehydrogenase assay kit. Walnuts decreased mitochondrial dysfunction, B-cell lymphoma 2 (Bcl-2)-associated X (Bax) protein levels, and cytochrome c release from mitochondria, while increasing Bcl-2 protein levels using immunofluorescence, Western blot, or kit analysis. Moreover, walnuts inhibited caspase-3 activity, indicating an inhibition of the apoptotic cascade, and induced the expression of heme oxygenase and NAD(P)H dehydrogenase via NF-E2-related factor-2 activation using immunofluorescence or Western blot analysis. CONCLUSION: Together, these results demonstrate that walnuts can protect human epidermal keratinocytes against UVB-induced mitochondria-mediated apoptosis by regulating ROS elimination pathways.


Asunto(s)
Apoptosis/efectos de los fármacos , Juglans/química , Queratinocitos/efectos de los fármacos , Extractos Vegetales/farmacología , Apoptosis/efectos de la radiación , Western Blotting , Caspasa 3/metabolismo , Línea Celular , Citocromos c/metabolismo , Relación Dosis-Respuesta a Droga , Epidermis/efectos de los fármacos , Epidermis/efectos de la radiación , Técnica del Anticuerpo Fluorescente , Humanos , Queratinocitos/patología , Queratinocitos/efectos de la radiación , L-Lactato Deshidrogenasa/metabolismo , Mitocondrias/efectos de los fármacos , Mitocondrias/patología , Mitocondrias/efectos de la radiación , Extractos Vegetales/administración & dosificación , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Semillas , Rayos Ultravioleta/efectos adversos , Regulación hacia Arriba/efectos de los fármacos , Proteína X Asociada a bcl-2/metabolismo
7.
Endoscopy ; 45(3): 202-7, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23381948

RESUMEN

BACKGROUND AND STUDY AIMS: Post-polypectomy coagulation syndrome (PPCS) is a well known complication of colonoscopic polypectomy. However, no previous studies have reported on the clinical outcomes or risk factors of PPCS. The aim of the current study was to analyze the clinical outcomes and risk factors of PPCS developing after a colonoscopic polypectomy. PATIENTS AND METHODS: Data for all patients who underwent colonoscopic polypectomies and required hospitalization in nine university hospitals were analyzed retrospectively. The incidence, clinicopathological characteristics, and clinical outcomes of PPCS cases were examined. Additionally, patients who developed PPCS were compared with controls who were matched by age and sex, in order to assess for possible risk factors. RESULTS: The rate of PPCS that required hospitalization after colonoscopic polypectomy was 0.7/1000. All patients with PPCS were treated medically without the need for surgical interventions. The median durations of therapeutic fasting, hospitalization, and antibiotic use were 3 days, 5.5 days, and 7 days, respectively. The rates of major PPCS and mortality were 2.9 % and 0 %, respectively. On multivariate analysis, hypertension (OR = 3.023, 95 %CI 1.034 - 8.832), large lesion size (OR = 2.855, 95 %CI 1.027 - 7.937), and non-polypoid configuration (OR = 3.332, 95 %CI 1.029 - 10.791) were found to be independent risk factors related to the development of PPCS. CONCLUSIONS: In this study, the rates of major PPCS and mortality were only 2.9 % and 0 %, respectively. Hypertension, large lesion size, and non-polypoid configuration of the lesion were independently associated with PPCS. Therefore, patients may be reassured by the excellent prognosis of PPCS, while endoscopists should be especially careful when performing colonoscopic polypectomies in patients with hypertension or large and non-polypoid lesions.


Asunto(s)
Dolor Abdominal/etiología , Pólipos del Colon/cirugía , Colonoscopía/efectos adversos , Electrocoagulación/efectos adversos , Adulto , Anciano , Estudios de Casos y Controles , Pólipos del Colon/patología , Femenino , Fiebre/etiología , Humanos , Hipertensión/complicaciones , Tiempo de Internación , Leucocitosis/etiología , Masculino , Persona de Mediana Edad , Peritonitis/etiología , Estudios Retrospectivos , Factores de Riesgo , Estadísticas no Paramétricas , Síndrome
8.
Herz ; 38(3): 306-8, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-23052903

RESUMEN

Klinefelter's syndrome, which is characterized by small testes, gynecomastia, hypogonadism, and infertility, is the most common cause of primary testicular failure, and commonly has an XXY karyotype. Deep vein thrombosis and thomboembolic events are a rare occurrence in these patients. Although the exact mechanism is not completely understood, it is thought that increased thromboembolic risk in hypogonadic men can be explained by hypofibrinolysis resulting from androgen deficiency. We present the case of a 48-year-old man with Klinefelter's syndrome who experienced recurrent episodes of deep venous thrombosis and pulmonary embolism while undergoing therapeutic anticoagulation. Our report discusses this association and management of the prothrombotic state in patients with Klinefelter's syndrome.


Asunto(s)
Fibrinolíticos/uso terapéutico , Síndrome de Klinefelter/diagnóstico , Síndrome de Klinefelter/terapia , Embolia Pulmonar/diagnóstico , Embolia Pulmonar/prevención & control , Trombosis de la Vena/diagnóstico , Trombosis de la Vena/prevención & control , Humanos , Masculino , Persona de Mediana Edad , Recurrencia , Resultado del Tratamiento
10.
Med Oral Patol Oral Cir Bucal ; 16(5): e651-6, 2011 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-20729798

RESUMEN

Odontogenic ghost cell carcinoma (OGCC), a malignant counterpart of the odontogenic ghost cell tumor (OGCT), with aggressive growth characteristics, is exceedingly rare. A painful swelling in the jaw with local paresthesia is the most common symptom. We described a case of 47-year Korean woman who had a rare central epithelial odontogenic ghost cell carcinoma which recurred at reconstructed fibular flap. Immunohistochemical differences between OGCT and OGCC analyzed using primary and recurred surgical specimen. On the basis of this case, the tumor started as an OGCT and transformed into OGCC with highly aggressive, rapidly growing, infiltrative tumors. Our findings suggest that some of the cytokines produced by ghost cells may play important roles in causing extensive bone resorption in the odontogenic ghost cell carcinoma. Wide local excision with histologically clean margins is the treatment mode of selection. Also, we recommend close long-term surveillance of OGCT because of high recurrence and potential for malignancy transformation.


Asunto(s)
Neoplasias Mandibulares/patología , Recurrencia Local de Neoplasia/patología , Tumores Odontogénicos/patología , Colgajos Quirúrgicos , Femenino , Peroné/trasplante , Humanos , Inmunohistoquímica , Neoplasias Mandibulares/cirugía , Persona de Mediana Edad , Tumores Odontogénicos/cirugía
11.
J Viral Hepat ; 17(3): 171-7, 2010 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-19678894

RESUMEN

We determined the virologic response, incidence of entecavir resistance, and evolution of lamivudine and adefovir-resistant mutants during entecavir (ETV) therapy in adefovir-refractory patients with prior lamivudine resistance. Forty adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance who had received entecavir for > or = 6 months were included and monitored for virologic response and entecavir resistance. Ten per cent of patients achieved HBV DNA < 50 copies/mL by PCR after 24 weeks of ETV therapy, and an initial virologic response was observed in 12 of 40 patients (30%). Higher pretreatment ALT (P = 0.039) and the presence of the rtL180M mutation (P = 0.038) were associated with an initial virologic response. During a mean follow-up of 11.4 months, four patients (10%) experienced virologic breakthrough, while ETV-resistant mutants were detected in six patients (15%). YMDD and adefovir-resistant mutants were detected in 57 and 35% of patients at baseline, respectively. At 48 weeks of therapy, 96 and 4% of patients had YMDD and adefovir-resistant mutants, respectively. These data suggest an early development of ETV resistance and low antiviral response during ETV therapy in adefovir-refractory patients with prior lamivudine resistance.


Asunto(s)
Adenina/análogos & derivados , Antivirales/uso terapéutico , Farmacorresistencia Viral , Guanina/análogos & derivados , Virus de la Hepatitis B/efectos de los fármacos , Hepatitis B Crónica/tratamiento farmacológico , Lamivudine/farmacología , Organofosfonatos/farmacología , Adenina/farmacología , Adulto , Antivirales/farmacología , ADN Viral/sangre , Femenino , Estudios de Seguimiento , Guanina/uso terapéutico , Hepatitis B Crónica/virología , Humanos , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Carga Viral
12.
Br J Dermatol ; 162(6): 1251-60, 2010 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20302580

RESUMEN

BACKGROUND: The active form of vitamin D(3) , calcitriol, is widely used for the treatment of psoriasis, with or without topical corticosteroids. Topical corticosteroids are known to disrupt permeability and antimicrobial barriers, even with short-term use. Yet, the effect of topical calcitriol on epidermal permeability and antimicrobial barriers disrupted by topical corticosteroids has not been determined. OBJECTIVES: To examine the effect of calcitriol on epidermal permeability and antimicrobial barrier function that has been impaired by corticosteroids, as well as to elucidate the mechanism of improvement. MATERIAL AND METHODS: Topical calcitriol or the control vehicle was applied to each flank of hairless mice 20 min after treatment with topical clobetasol propionate and repeated every 12 h for 3·5 days. Barrier function assessment, Nile red staining, electron microscopy, immunohistochemistry, Western blotting, and real-time reverse transcriptase-polymerase chain reaction studies were performed 24 h after the last application. RESULTS: Epidermis co-treated with topical calcitriol showed an improvement of stratum corneum integrity and barrier recovery, more intense fluorescence staining with Nile red, and an increase in lamellar body (LB) maturation and density, as well as upregulation of major epidermal lipid synthesis-related enzymes (3-hydroxy-3-methylglutaryl-CoA, serine-palmitoyl transferase and fatty acid synthase), mouse beta-defensin 3, cathelin-related antimicrobial peptide and vitamin D receptor. CONCLUSIONS: We found that topical calcitriol restored both the epidermal permeability and antimicrobial barrier that had been impaired by corticosteroids. This restoration was mediated by both an activation of the cutaneous vitamin D pathway and an increase of epidermal lipids and antimicrobial peptides, promoted by the formation of the LB and the activity of epidermal lipid synthesis-related enzymes.


Asunto(s)
Calcitriol/farmacología , Agonistas de los Canales de Calcio/farmacología , Epidermis/efectos de los fármacos , Administración Tópica , Animales , Western Blotting , Calcitriol/uso terapéutico , Agonistas de los Canales de Calcio/uso terapéutico , Clobetasol/análogos & derivados , Clobetasol/farmacología , Modelos Animales de Enfermedad , Enzimas/metabolismo , Epidermis/metabolismo , Epidermis/patología , Femenino , Glucocorticoides/farmacología , Inmunohistoquímica , Ratones , Ratones Pelados , Microscopía Electrónica , Oxazinas/administración & dosificación , Permeabilidad/efectos de los fármacos , Reacción en Cadena de la Polimerasa/métodos , Absorción Cutánea/efectos de los fármacos , Regulación hacia Arriba
13.
J Physiol Pharmacol ; 70(3)2019 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-31566193

RESUMEN

Stress-related mucosal disease (SRMD), or stress ulceration, is a group of conditions ranging from stress-related superficial gastric mucosal damage to deep gastric ulcers that are primarily correlated with mucosal ischemia, and pharmacologic interventions that optimize tissue perfusion or preserve defensive mucus aim to decrease the occurrence of conditions, such as gastric acidity, or enhance gastric defenses. However, the identification of multifactorial pathogenesis may be effective in preventing SMRD, and the use of stress prophylaxis is generally preferred. Since threonine is a component in the polymerization and synthesis of gastric mucin and possibly enhanced defense actions and lignin may provide structural support for defense and antioxidative function, we hypothesized that dietary intake of threonine and/or lignin can enhance defense against SRMD. The water immersion-restraint stress (WIRS) was used in rats and additional groups were pretreated with threonine alone or the combination of threonine and lignin. Based on gross and microscopic evaluations, threonine alone or the combination of threonine and lignin, a natural antioxidant, significantly reduced the development of SRMD (P < 0.05). According to molecular explorations, the levels of inflammatory mediators, such as interleukin (IL)-8, IL-6, IL-1ß, inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNF-α), and interferon gamma (IFN-γ), all of which are mediators that play a significant role in controlling WIRS, significantly decreased in the groups pretreated with either threonine alone or the combination of threonine and lignin (P < 0.01). WIRS significantly increased apoptosis in the stomach. However, the apoptotic index significantly decreased with threonine pretreatment. According to periodic acid Schiff staining results, the expression of gastric mucin was significantly preserved in groups pretreated with threonine but remarkedly decreased in the WIRS group. The gastric heme oxygenase-1 levels significantly increased in the group treated with threonine. In conclusion, the dietary intake of threonine or the combination of threonine and lignin is effective in preventing SRMD.


Asunto(s)
Mucosa Gástrica/efectos de los fármacos , Estrés Fisiológico/efectos de los fármacos , Treonina/farmacología , Animales , Antioxidantes/farmacología , Apoptosis/efectos de los fármacos , Dieta , Mediadores de Inflamación/metabolismo , Lignina/metabolismo , Ratas , Ratas Sprague-Dawley , Estómago/efectos de los fármacos , Úlcera Gástrica/tratamiento farmacológico , Úlcera Gástrica/metabolismo
14.
Theriogenology ; 70(9): 1431-8, 2008 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-18804273

RESUMEN

We used nuclear transfer (NT) to develop transgenic female pigs harboring goat beta-casein promoter/human granulocyte-macrophage colony stimulating factor (hGM-CSF). The expression of hGM-CSF was specific to the mammary gland, and the glycosylation-derived size heterogeneity corresponded to that of the native human protein. Although various cell types have been used to generate cloned animals, little is currently known about the potential use of fibroblasts derived from a cloned fetus as donor cells for nuclear transfer. The developmental potential of porcine cloned fetal fibroblasts transfected with hGM-CSF was evaluated in the present study. Cloned fetal fibroblasts were isolated from a recipient following the transplantation of NT embryos. The cells were transfected with both hGM-CSF and the neomycin resistance gene in order to be used as donor cells for NT. Reconstructed embryos were implanted into six sows during estrus; two of the recipient sows delivered seven healthy female piglets with the hGM-CSF gene (confirmed with PCR and fluorescent in situ hybridization) and microsatellite analysis confirmed that the clones were genetically identical to the donor cells. The expression of hGM-CSF was strong in the mammary glands of a transgenic pig that died a few days prior to parturition (110 d after AI). These results demonstrated that somatic cells derived from a cloned fetus can be used to produce recloned and transgenic pigs.


Asunto(s)
Animales Modificados Genéticamente , Fibroblastos/citología , Factor Estimulante de Colonias de Granulocitos y Macrófagos/genética , Técnicas de Transferencia Nuclear/veterinaria , Porcinos/genética , Animales , Clonación de Organismos , Femenino , Humanos , Embarazo
15.
J Clin Invest ; 94(5): 1757-63, 1994 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-7525647

RESUMEN

Treatment of wounds with pharmacologic doses of the BB homodimeric form of recombinant PDGF (rPDGF-BB) induces the recruitment, activation, and proliferation of mesenchymal cells, resulting in the deposition of provisional, and subsequently collagen-containing extracellular matrix. In preliminary experiments with an in vitro growth chamber model in the rat consisting of a silicone shell containing a dissected femoral vascular bundle, we found that rPDGF-BB incorporated into a rapidly dissolving collagen type I film induces the generation of a marked, but transient amount of de novo tissue around the femoral vascular bundle. In the present studies, the new tissue generated around the femoral vascular bundle was wrapped with a full thickness syngeneic skin graft to determine if functional support of the graft would lead to sustained maintenance of the underlying generated tissue and create an epithelialized soft tissue appendage. The tissue generated after a single application of rPDGF-BB was skin grafted on the 10th day, exteriorized 20 d later, and observed for an additional month. This led to the formation of soft tissue appendages which demonstrated marked neovascularization, fibroblast migration and proliferation, and increased glycosaminoglycan, fibronectin, and collagen fibril deposition, now leading to preservation of the newly generated tissue. In contrast, minimal new tissue was generated in control-treated vascular bundles or bundles treated with inactive PDGF-BB, and grafting with skin failed to sustain the underlying tissue. Thus, rPDGF-BB coupled with skin grafting induced the formation of functional large soft tissue appendages which are potentially useful clinically to fill tissue defects or to serve as a cell delivery system for transfected genes.


Asunto(s)
Matriz Extracelular/fisiología , Neovascularización Patológica/inducido químicamente , Factor de Crecimiento Derivado de Plaquetas/farmacología , Animales , División Celular/efectos de los fármacos , Colágeno/metabolismo , Terapia Genética , Masculino , Ratas , Ratas Endogámicas Lew , Proteínas Recombinantes/farmacología , Trasplante de Piel
16.
Mol Cell Biol ; 21(17): 5790-6, 2001 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-11486018

RESUMEN

Sip4 is a Zn(2)Cys(6) transcriptional activator that binds to the carbon source-responsive elements of gluconeogenic genes in Saccharomyces cerevisiae. The Snf1 protein kinase interacts with Sip4 and regulates its phosphorylation and activator function in response to glucose limitation; however, evidence suggested that another kinase also regulates Sip4. Here we examine the role of the Srb10 kinase, a component of the RNA polymerase II holoenzyme that has been primarily implicated in transcriptional repression but also positively regulates Gal4. We show that Srb10 is required for phosphorylation of Sip4 during growth in nonfermentable carbon sources and that the catalytic activity of Srb10 stimulates the ability of LexA-Sip4 to activate transcription of a reporter. Srb10 and Sip4 coimmunoprecipitate from cell extracts and interact in two-hybrid assays, suggesting that Srb10 regulates Sip4 directly. We also present evidence that the Srb10 and Snf1 kinases interact with different regions of Sip4. These findings support the view that the Srb10 kinase not only plays negative roles in transcriptional control but also has broad positive roles during growth in carbon sources other than glucose.


Asunto(s)
Quinasas Ciclina-Dependientes/metabolismo , Proteínas de Saccharomyces cerevisiae , Transactivadores/metabolismo , Dedos de Zinc , Proteínas Bacterianas/genética , Proteínas Bacterianas/metabolismo , Factores de Transcripción con Cremalleras de Leucina de Carácter Básico , Quinasa 8 Dependiente de Ciclina , Quinasas Ciclina-Dependientes/genética , Proteínas Fúngicas/metabolismo , Glucosa/metabolismo , Mutagénesis , Fosforilación , Pruebas de Precipitina , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Saccharomyces cerevisiae/genética , Saccharomyces cerevisiae/metabolismo , Serina Endopeptidasas/genética , Serina Endopeptidasas/metabolismo , Transactivadores/genética , Activación Transcripcional , Técnicas del Sistema de Dos Híbridos
18.
J Int Med Res ; 35(6): 827-35, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-18034996

RESUMEN

Restriction fragment mass polymorphism (RFMP) was applied to pooled DNA for selecting informative single nucleotide polymorphisms (SNPs). A total of 225 coding non-synonymous SNPs (cnSNPs) from immunomodulating genes known to be involved in the pathogenesis of asthma were selected from the National Center for Biotechnology Information's (NCBI) SNP database (dbSNP). DNA samples from 200 healthy Koreans were pooled, amplified by polymerase chain reaction, digested with restriction enzymes and the fragments analysed by mass spectrometry. Only 30 of the 225 cnSNPs (13.3%) were informative, i.e.had a minor allele frequency>10%. The percentage of informative cnSNPs varied according to the validation status of the dbSNP, being 42.3% (22/52) when validated by multiple submissions and frequency data, 8.7% (2/23) when validated by multiple submissions alone and 9.1% (3/33) when validated by frequency data alone. Most of the 112 unvalidated cnSNPs were not informative. In conclusion, the RFMP method using pooled DNA is useful in selecting informative SNPs, as also is validation status in the dbSNP.


Asunto(s)
Asma/genética , Pruebas Genéticas , Reacción en Cadena de la Polimerasa/métodos , Polimorfismo de Nucleótido Simple , Frecuencia de los Genes , Marcadores Genéticos , Humanos , Corea (Geográfico) , Peso Molecular , Reproducibilidad de los Resultados , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción
19.
Gut ; 55(10): 1488-95, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16461777

RESUMEN

BACKGROUND: Adefovir dipivoxil (ADV) is a potent nucleotide analogue against both the wild-type and lamivudine (LMV) resistant hepatitis B virus (HBV). The cumulative incidence of ADV resistant mutations in the nucleoside/-tide treatment naive chronic hepatitis B patient (CHB) at weeks 48, 96, and 144 was 0, 0.8-3%, and approximately 5.9%, respectively. AIMS: The aim of this study was to characterise the genotypic and phenotypic mutation profiles to ADV in 67 LMV resistant CHB patients who were treated with ADV. METHODS: Serum HBV DNA was quantified by real time polymerase chain reaction. The ADV mutant was detected using matrix assisted laser desorption/ionisation time of flight mass spectrometry based genotyping assays, termed restriction fragment mass polymorphism (RFMP). RESULTS: RFMP analysis revealed that a total of 11 amino acid substitutions developed in the rt domain of the HBV polymerase in nine patients. The cumulative incidence of genotypic ADV resistance at months 12 and 24 was 6.4% and 25.4%, respectively. The rtA181V, rtN236T, and rtA181T mutations were detected in five, four, and two of the 67 patients at treatment months 12-17, 3-19, and 7-20, respectively. Serial quantification of serum HBV DNA revealed that two patients with the rtA181V mutation, with or without the rtN236T mutation, and one patient with the rtA181T mutation displayed HBV DNA rebound. CONCLUSION: Emergence of the ADV mutation in LMV resistant patients who are treated with ADV appeared to present earlier and more frequently than was reported in previous studies on nucleoside/-tide treatment naive patients.


Asunto(s)
Adenina/análogos & derivados , Hepatitis B Crónica/tratamiento farmacológico , Lamivudine/uso terapéutico , Organofosfonatos/uso terapéutico , Inhibidores de la Transcriptasa Inversa/uso terapéutico , Adenina/uso terapéutico , Adulto , Farmacorresistencia Viral/genética , Femenino , Genotipo , Hepatitis B Crónica/genética , Humanos , Masculino , Persona de Mediana Edad , Mutación/genética , Fenotipo , Estudios Retrospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA